A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS) ; volume:24 ; number:1 ; day:13 ; month:11 ; year:2023 ; pages:1-11 ; date:12.2023
BMC pharmacology & toxicology ; 24, Heft 1 (13.11.2023), 1-11, 12.2023
- Urheber
-
Zou, Shu-peng
Yang, Hai-yun
Ouyang, Meng-ling
Cheng, Qian
Shi, Xuan
Sun, Ming-hui
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-023-00702-w
- URN
-
urn:nbn:de:101:1-2024013013572033162281
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zou, Shu-peng
- Yang, Hai-yun
- Ouyang, Meng-ling
- Cheng, Qian
- Shi, Xuan
- Sun, Ming-hui
- SpringerLink (Online service)
Ähnliche Objekte (12)
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system
Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System
Standardizing adverse drug event reporting data
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system